Emerging pharmacological treatment options for MAFLD.
Ángela RojasCarmen Lara-RomeroRocío Muñoz-HernándezSheila GatoJavier AmpueroManuel Romero-GómezPublished in: Therapeutic advances in endocrinology and metabolism (2022)
Metabolic dysfunction-associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitus, and at least two metabolic risk factors, such as hypertension, hypertriglyceridemia, hypercholesterolemia, insulin resistance, and cardiovascular risk, increasing the risk of mortality. The excessive accumulation of fat comprises apoptosis, necrosis, inflammation and ballooning degeneration progressing to fibrosis, cirrhosis, and liver decompensations including hepatocellular carcinoma development. The limitation of approved drugs to prevent MAFLD progression is a paradigm. This review focuses on recent pathways and targets with evidence results in phase II/III clinical trials.
Keyphrases
- risk factors
- phase ii
- clinical trial
- insulin resistance
- oxidative stress
- weight gain
- adipose tissue
- weight loss
- metabolic syndrome
- open label
- type diabetes
- blood pressure
- cardiovascular events
- high fat diet induced
- high fat diet
- glycemic control
- randomized controlled trial
- fatty acid
- physical activity
- polycystic ovary syndrome
- skeletal muscle
- phase iii
- cell death
- body mass index
- cardiovascular risk factors
- study protocol
- double blind
- pi k akt